{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:40:50Z","timestamp":1765546850193,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T00:00:00Z","timestamp":1634342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T00:00:00Z","timestamp":1634342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS066801; R01AG 054325"],"award-info":[{"award-number":["R01NS066801; R01AG 054325"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroimmune Pharmacol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s11481-021-10013-8","type":"journal-article","created":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T19:06:34Z","timestamp":1634411194000},"page":"718-721","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cannabis\/Cannabinoids for Treating COVID-19 Associated Neuropsychiatric Complications"],"prefix":"10.1007","volume":"16","author":[{"given":"Jag H.","family":"Khalsa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay B.","family":"Maggirwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Bunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,16]]},"reference":[{"issue":"2","key":"10013_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11481-020-09924-9","volume":"15","author":"A Acharya","year":"2020","unstructured":"Acharya A, Kevadiya BD, Gendelman HE et al (2020) SARS-Cov-2 infection leads to neurological dysfunction. Neuroimmune Pharmacol 15(2):167\u2013173","journal-title":"Neuroimmune Pharmacol"},{"issue":"4","key":"10013_CR2","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/j.1600-0447.2011.01687.x","volume":"124","author":"CH Ashton","year":"2011","unstructured":"Ashton CH, Moore PB (2011) Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatric Scand 124(4):250\u2013261","journal-title":"Acta Psychiatric Scand"},{"key":"10013_CR3","doi-asserted-by":"publisher","unstructured":"Ashton CH, Moore PB, Gallagher P, Young AH (2005) Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. J Psychopharmacol (3): 293\u2013300. https:\/\/doi.org\/10.1177\/0269881105051541. PMID:15888515.","DOI":"10.1177\/0269881105051541"},{"key":"10013_CR4","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","volume":"12","author":"EM Blessing","year":"2015","unstructured":"Blessing EM, Steenkamp MM, Manzanares J et al (2015) Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics 12:825\u2013836","journal-title":"Neurotherapeutics"},{"issue":"7","key":"10013_CR5","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1377\/hlthaff.2015.1661","volume":"35","author":"AC Bradford","year":"2016","unstructured":"Bradford AC, Bradford WD (2016) Medical marijuana laws reduce prescription medication use in medicare part D. Health Aff Proj Hope 35(7):1230\u20131236","journal-title":"Health Aff Proj Hope"},{"key":"10013_CR6","doi-asserted-by":"publisher","first-page":"16865","DOI":"10.1074\/jbc.273.27.16865","volume":"273","author":"CS Breivogel","year":"1998","unstructured":"Breivogel CS, Selley DE, Childers SR (1998) Cannabinoid receptor agonist efficacy for stimulating [35S]GTPgammaS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J Biol Chem 273:16865\u201316873","journal-title":"J Biol Chem"},{"key":"10013_CR7","unstructured":"Centers for Disease Control and Prevention, Coronavirus disease 2019 (COVID-19), People with certain medical conditions, CDC, 2020. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/need-extra-precautions\/people-with-medical-conditions.html. Accessed 07 March 2020"},{"issue":"371","key":"10013_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3862","volume":"23","author":"M Cevik","year":"2020","unstructured":"Cevik M, Kuppalli K, Kindrachuk J, Peiris M (2020) Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ 23(371):m3862. https:\/\/doi.org\/10.1136\/bmj.m3862","journal-title":"BMJ"},{"key":"10013_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3389\/fpsyt.2019.00063","volume":"10","author":"Y Chye","year":"2019","unstructured":"Chye Y, Christensen E, Solowij N et al (2019) The endocannabinoid system and cannabidiol\u2019s promise for the treatment of substance use disorder. Front Psychiatry 10:63. https:\/\/doi.org\/10.3389\/fpsyt.2019.00063","journal-title":"Front Psychiatry"},{"key":"10013_CR10","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1161\/CIRCULATIONAHA.120.046941","volume":"141","author":"KJ Clerkin","year":"2020","unstructured":"Clerkin KJ, Fried JA, Raikhelkar J et al (2020) Covid-19 and cardiovascular disease. Circulation 141:1648\u20131655","journal-title":"Circulation"},{"key":"10013_CR11","unstructured":"Coronavirus Resource Center, Coronavirus Case Tracker, Johns Hopkins University, Baltimore, Maryland. 2021. https:\/\/coronavirus.jhu.edu\/. Accessed 07 May 2021"},{"issue":"6","key":"10013_CR12","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.tins.2020.04.004","volume":"43","author":"FG De Felice","year":"2020","unstructured":"De Felice FG, Tovar-Moll F, Moll J et al (2020) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the central nervous system. Trends Neurosci 43(6):355\u2013357","journal-title":"Trends Neurosci"},{"key":"10013_CR13","doi-asserted-by":"publisher","first-page":"953","DOI":"10.2174\/1871527313666140612114838","volume":"13","author":"AR de Mello Schier","year":"2014","unstructured":"de Mello Schier AR, de Oliveira Ribeiro NP, Coutinho DS et al (2014) Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa. CNS Neurol Disord Drug Targets 13:953\u2013960","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10013_CR14","first-page":"1","volume":"103","author":"MA ElSohly","year":"2017","unstructured":"ElSohly MA, Radwan MM, Gul W, Chandra S, Galal A (2017) Phytochemistry of Cannabis sativa L. Prog Chem Org Nat Prod 103:1\u201336","journal-title":"Prog Chem Org Nat Prod"},{"issue":"4","key":"10013_CR15","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1001\/jamainternmed.2014.8006","volume":"175","author":"JW Finney","year":"2015","unstructured":"Finney JW, Humphreys K, Harris AHS (2015) What ecologic analyses cannot tell us about medical marijuana legalization and opioid pain medication mortality. JAMA Intern Med 175(4):655\u2013656","journal-title":"JAMA Intern Med"},{"key":"10013_CR16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1021\/ja00730a036","volume":"93","author":"Y Gaoni","year":"1971","unstructured":"Gaoni Y, Mechoulam R (1971) The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc 93:217\u2013224","journal-title":"J Am Chem Soc"},{"key":"10013_CR17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1055\/s-0044-100798","volume":"84","author":"W Gul","year":"2018","unstructured":"Gul W, Gul SW, Chandra S, Lata H, Ibrahim EA, ElSohly MA (2018) Detection and quantification of cannabinoids in extracts of cannabis sativa roots using LC-MS\/MS. Planta Med 84:267\u2013271","journal-title":"Planta Med"},{"key":"10013_CR18","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1111\/add.14243","volume":"113","author":"C Hindocha","year":"2018","unstructured":"Hindocha C, Freeman TP, Grabski M et al (2018) Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal. Addiction 113:1696\u20131705","journal-title":"Addiction"},{"issue":"1","key":"10013_CR19","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/jmv.26232","volume":"93","author":"B Hu","year":"2021","unstructured":"Hu B, Huang S, Yin L (2021) The cytokine storm and COVID-19. J Med Virol 93(1):250\u2013256. https:\/\/doi.org\/10.1002\/jmv.26232","journal-title":"J Med Virol"},{"issue":"11","key":"10013_CR20","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1176\/appi.ajp.2019.18101191","volume":"176","author":"YL Hurd","year":"2019","unstructured":"Hurd YL, Spriggs S, Alishayev J et al (2019) Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. Am J Psychiatry 176(11):911\u2013922","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10013_CR21","first-page":"5","volume":"2","author":"J Khalsa","year":"2019","unstructured":"Khalsa J, Bunt G, Galanter M, Wetterau N (2019) Cannabidiol as medicine: are we there? Int Addict Rev 2(2):5\u201318","journal-title":"Int Addict Rev"},{"key":"10013_CR22","unstructured":"Krizinger A, Kearney A, Hamel L, Brodie M (2020) KFF Health Tracking Poll-Early April 2020: the impact of coronavirus on life in America. https:\/\/www.kff.org\/coronavirus-covid-19\/report\/kff-health-tracking-poll-early-april-2020\/. Accessed 07 May 2020"},{"key":"10013_CR23","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1089\/can.2020.0054","volume":"5","author":"MH Land","year":"2020","unstructured":"Land MH, MacNair L, Thomas BF, Peters EN, Bonn-Miller MO (2020) Letter to the editor: possible drug-drug interactions between cannabinoids and candidate COVID-19 drugs. Cannabis Cannabinoid Res 5:340. https:\/\/doi.org\/10.1089\/can.2020.0054","journal-title":"Cannabis Cannabinoid Res"},{"key":"10013_CR24","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/BF02862859","volume":"28","author":"HL Li","year":"1974","unstructured":"Li HL (1974) An archaeological and botanical account of cannabis in China. Econ Bot 28:437\u2013448","journal-title":"Econ Bot"},{"key":"10013_CR25","first-page":"175","volume":"25","author":"R Mechoulam","year":"1967","unstructured":"Mechoulam R, Gaoni Y (1967) Recent advances in the chemistry of hashish. Fortschr Chem Org Naturst 25:175\u2013213","journal-title":"Fortschr Chem Org Naturst"},{"key":"10013_CR26","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.addbeh.2013.03.011","volume":"38","author":"CJ Morgan","year":"2013","unstructured":"Morgan CJ, Das RK, Joye A et al (2013) Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav 38:2433\u20132436","journal-title":"Addict Behav"},{"key":"10013_CR27","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1037\/a0013278","volume":"122","author":"E Murillo-Rodriguez","year":"2008","unstructured":"Murillo-Rodriguez E, Millan-Aldaco D, Palomero-Rivero M, Mechoulam R et al (2008) The nonpsychoactive Cannabis constituent cannabidiol is a wake-inducing agent. Behav Neurosci 122:1378\u20131382","journal-title":"Behav Neurosci"},{"key":"10013_CR28","doi-asserted-by":"publisher","unstructured":"Nguyen LC, Yang D, Nicolaescu V et al (2021) Cannabidiol inhibits SARS-CoV-2 replication and promotes the host innate immune response. Preprint. bioRxiv. https:\/\/doi.org\/10.1101\/2021.03.10.432967","DOI":"10.1101\/2021.03.10.432967"},{"key":"10013_CR29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.7812\/TPP\/16-005","volume":"20","author":"S Shannon","year":"2016","unstructured":"Shannon S, Opila-Lehman J (2016) Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: a case report. Perm J 20:108\u2013111","journal-title":"Perm J"},{"key":"10013_CR30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/02791072.1998.10399682","volume":"30","author":"DE Smith","year":"1998","unstructured":"Smith DE (1998) Review of the American Medical Association Council on Scientific Affairs report on medical marijuana. J Psychoactive Drugs 30:127\u2013136","journal-title":"J Psychoactive Drugs"},{"key":"10013_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1089\/can.2017.0043","volume":"3","author":"N Solowij","year":"2018","unstructured":"Solowij N, Broyd SJ, Beale C et al (2018) Therapeutic effects of prolonged cannabidiol treatment on psychological symptoms and cognitive function in regular cannabis users: a pragmatic open-label clinical trial. Cannabis Cannabinoid Res 3:21\u201334","journal-title":"Cannabis Cannabinoid Res"},{"key":"10013_CR32","doi-asserted-by":"publisher","first-page":"e0190768","DOI":"10.1371\/journal.pone.0190768","volume":"13","author":"JM Trigo","year":"2018","unstructured":"Trigo JM, Soliman A, Quilty LC et al (2018) Nabiximols combined with motivational enhancement\/cognitive behavioral therapy for the treatment of cannabis dependence: a pilot randomized clinical trial. PLoS ONE 13:e0190768","journal-title":"PLoS ONE"},{"issue":"8","key":"10013_CR33","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s11739-020-02345-9","volume":"15","author":"Y Uno","year":"2020","unstructured":"Uno Y (2020) Camostat mesilate therapy for COVID-19. Intern Emerg Med 15(8):1577\u20131578. https:\/\/doi.org\/10.1007\/s11739-020-02345-9","journal-title":"Intern Emerg Med"},{"key":"10013_CR34","doi-asserted-by":"publisher","unstructured":"Varatharaj A, Thomas N, Ellul MA, et al. on behalf of the CoroNerve Study Group (2020) Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry. https:\/\/doi.org\/10.1016\/S2215-0366(20)30287-X","DOI":"10.1016\/S2215-0366(20)30287-X"},{"issue":"1","key":"10013_CR35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1089\/can.2018.0022","volume":"3","author":"B Weise","year":"2018","unstructured":"Weise B, Wilson-Poe AR (2018) Emerging evidence for cannabis\u2019 role in opioid use disorder. Cannabis Cannabinoid Res 3(1):179\u2013189","journal-title":"Cannabis Cannabinoid Res"},{"issue":"1","key":"10013_CR36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/ane.13266","volume":"142","author":"A Whittaker","year":"2020","unstructured":"Whittaker A, Anson M, Harky A et al (2020) Neurological manifestations of COVID19: a systematic review and current update. Acta Neurol Scand 142(1):14\u201322","journal-title":"Acta Neurol Scand"}],"container-title":["Journal of Neuroimmune Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-021-10013-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11481-021-10013-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-021-10013-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T08:09:40Z","timestamp":1640765380000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11481-021-10013-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,16]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10013"],"URL":"https:\/\/doi.org\/10.1007\/s11481-021-10013-8","relation":{},"ISSN":["1557-1890","1557-1904"],"issn-type":[{"type":"print","value":"1557-1890"},{"type":"electronic","value":"1557-1904"}],"subject":[],"published":{"date-parts":[[2021,10,16]]},"assertion":[{"value":"4 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None for JK, GB, SBM.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}